Intercollegiate Faculty of Biotechnology UG&MUG, University of Gdańsk, Abrahama 58, 80-307 Gdańsk, Poland.
Department of Otolaryngology, the Nicolaus Copernicus Hospital in Gdansk, Copernicus Healthcare Entity, Powstańców Warszawskich 1/2, 80-152 Gdansk, Poland.
Int J Mol Sci. 2024 Aug 13;25(16):8799. doi: 10.3390/ijms25168799.
Salivary gland tumors are highly variable in clinical presentation and histology. The World Health Organization (WHO) classifies 22 types of malignant and 11 types of benign tumors of the salivary glands. Diagnosis of salivary gland tumors is based on imaging (ultrasound, magnetic resonance imaging) and fine-needle aspiration biopsy, but the final diagnosis is based on histopathological examination of the removed tumor tissue. In this pilot study, we are testing a new approach to identifying peptide biomarkers in saliva that can be used to diagnose salivary gland tumors. The research material for the peptidomic studies was extracts from washings of neoplastic tissues and healthy tissues (control samples). At the same time, saliva samples from patients and healthy individuals were analyzed. The comparison of the peptidome composition of tissue extracts and saliva samples may allow the identification of potential peptide markers of salivary gland tumors in patients' saliva. The peptidome compositions extracted from 18 tumor and 18 healthy tissue samples, patients' saliva samples (11 samples), and healthy saliva samples (8 samples) were analyzed by LC-MS tandem mass spectrometry. A group of 109 peptides was identified that were present only in the tumor tissue extracts and in the patients' saliva samples. Some of the identified peptides were derived from proteins previously suggested as potential biomarkers of salivary gland tumors (ANXA1, BPIFA2, FGB, GAPDH, HSPB1, IGHG1, VIM) or tumors of other tissues or organs (SERPINA1, APOA2, CSTB, GSTP1, S100A8, S100A9, TPI1). Unfortunately, none of the identified peptides were present in all samples analyzed. This may be due to the high heterogeneity of this type of cancer. The surprising result was that extracts from tumor tissue did not contain peptides derived from salivary gland-specific proteins (STATH, SMR3B, HTN1, HTN3). These results could suggest that the developing tumor suppresses the production of proteins that are essential components of saliva.
唾液腺肿瘤在临床表现和组织学上具有高度可变性。世界卫生组织(WHO)将 22 种恶性和 11 种良性唾液腺肿瘤进行分类。唾液腺肿瘤的诊断基于影像学(超声、磁共振成像)和细针抽吸活检,但最终诊断基于切除肿瘤组织的组织病理学检查。在这项初步研究中,我们正在测试一种新方法来鉴定唾液中的肽生物标志物,这些标志物可用于诊断唾液腺肿瘤。肽组学研究的研究材料是来自肿瘤组织和健康组织(对照样本)冲洗液的提取物。同时,还分析了来自患者和健康个体的唾液样本。组织提取物和唾液样本的肽组组成的比较可能允许鉴定患者唾液中唾液腺肿瘤的潜在肽标记物。通过 LC-MS 串联质谱法分析了 18 个肿瘤和 18 个健康组织样本、患者唾液样本(11 个样本)和健康唾液样本(8 个样本)的提取物以及 109 个肽组。鉴定出一组仅存在于肿瘤组织提取物和患者唾液样本中的肽。一些鉴定出的肽来自先前被认为是唾液腺肿瘤(ANXA1、BPIFA2、FGB、GAPDH、HSPB1、IGHG1、VIM)或其他组织或器官肿瘤(SERPINA1、APOA2、CSTB、GSTP1、S100A8、S100A9、TPI1)的潜在生物标志物的蛋白质。不幸的是,在分析的所有样本中都没有发现鉴定出的肽。这可能是由于这种癌症的高度异质性。令人惊讶的结果是,肿瘤组织的提取物不包含来自唾液腺特异性蛋白质(STATH、SMR3B、HTN1、HTN3)的肽。这些结果可能表明,正在发育的肿瘤抑制了作为唾液重要成分的蛋白质的产生。